skip to content

Cambridge Immunology Network

Scientific Director of the Immunology Network at GSK, a novel model of industry-academia collaboration designed to drive major breakthroughs in applied immunology and broaden scientific insight.


Understanding the pathological impact of monocytes/macrophages in immune system disorders and developing therapeutics to modulate them.

The GSK Immunology Network
GSK has selected leading academic immunologists to join their R&D facility in Stevenage, UK, where they will work alongside GSK’s scientists while pursuing their own independent research programmes focused on basic immunology questions. They will have access to GSK’s technologies and research tools and, by connecting with GSK scientists, have the opportunity to expand their knowledge of drug discovery and translational research. Current research themes in the Immunology Catalyst include immunometabolism, innate immune cell signalling, myeloid cell development. Paul-Peter Tak, SVP and Chief Immunology Officer, GSK, is the programme sponsor. The Immunology Catalyst members are also supported by a network of leading immunologists at GSK and an external immunology board of world class immunologists including Professors Vijay Kuchroo, Jerry Nepom, Frank Nestle, Luke O’Neill, Fiona Powrie, Maria-Grazia Roncarolo, Pam Sharma, Hergen Spits. This is an ongoing programme and includes opportunities for postdoctoral training.



Key publications: 

Nuruddeen D. Lewis, Lori A. Patnaude, Josephine Pelletier, Donald Souza, Susan M. Lukas, F. James King, Jonathan D. Hill, Dimitria E. Stefanopoulos, Stefan G. Kauschke, Andre Broermann, Daniel Kuzmich, Christian Harcken, Eugene R. Hickey, Louise K. Modis. A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. PLoS One. 2014 Jun 26;9(6):e100883


Nuruddeen D. Lewis, Jonathon Hill, William Loging, Louise K. Modis. RNA sequencing of microglia and monocyte-derived macrophages from mice with experimental autoimmune encephalomyelitis illustrates a changing phenotype with disease course. J Neuroimmunol. 2014 Dec 15;277(1-2):26-38


Nuruddeen D. Lewis, Akalushi Muthukumarana, Steven E. Fogal, Laura Corradini, Dimitria E. Stefanopoulos, Prathima Adusumalli, Josephine Pelletier, Mark Panzenbeck, Karen Berg, Melissa Canfield, Brian Cook, Hossein Razavi, Shawn Anderson, Devan Allard, Michael Thibodeau, Paul Harrison, Christine Grimaldi, Donald Souza, Ryan M. Fryer, Louise K. Modis*, and Maryanne L. Brown. CCR1 plays a critical role in modulating pain through hematopoietic and non-hematopoietic cells PLoS One. 2014 Aug 29;9(8):e105883.*Corresponding author


Nuruddeen D. Lewis, Sokol A. Haxhinasto, Shawn M. Anderson, Dimitria E. Stefanopoulos, Steven E. Fogal, Prathima Adusumalli, Sudha N. Desai, Kelli R. Ryan, Lori A. Patnaude, Susan M. Lukas, Anthony J. Slavin, Maryanne L. Brown and Louise K. ModisCirculating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J. Immunol. 2013;190.3533-3540.


S.Sarrazin, N. Mossadegh-Keller, T. Fukao, A.Aziz, F. Mourcin, L.Vanhille, L. Kelly Modis, P. Kastner, S. Chan, E. Duprez, C. Otto, and M.H. Sieweke. (2009) MafB restricts M-CSF dependent myeloid commitment divisions of hematopoietic stem cells. Cell. 138, 300-14.


Dr Louise   Modis
Not available for consultancy